Cabaletta Q1 2024: $223.8M cash, no CRS/ICANS in CABA-201 trials; clinical data at EULAR June

Cabaletta Bio, Inc.

Cash, cash equivalents and short-term investments of $223.8M as of March 31, 2024, down from $241.2M Dec 31, 2023; runway into H1 2026.
R&D expense $22.0M (vs $12.4M YoY); G&A $6.1M (vs $4.5M YoY).
No CRS or ICANS of any grade observed in first patients dosed in RESET-Myositis and RESET-SLE trials.
Initial clinical data from first patients in myositis and SLE to be presented at EULAR 2024 Congress in June.
FDA granted Fast Track, Orphan Drug, and Rare Pediatric Disease designations for CABA-201 in myositis; Fast Track and Orphan for SSc.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.